310 Participants Needed

Ultrasound + Photoacoustic Imaging for Ovarian Health

Recruiting at 1 trial location
CL
Overseen ByCary L Siegel, M.D.
Age: 18+
Sex: Female
Trial Phase: Academic
Sponsor: Washington University School of Medicine
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests whether a new imaging method, called photoacoustic imaging, can help doctors avoid unnecessary surgeries for ovarian conditions while still accurately detecting cancer. By combining photoacoustic imaging with ultrasound (also known as sonography), researchers aim to catch ovarian cancer early, especially in individuals at high risk. Suitable candidates for this trial include those needing surgery involving one or both ovaries and having a genetic mutation linked to ovarian cancer. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could enhance early cancer detection.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that this photoacoustic imaging/ultrasound technique is safe for ovarian health?

Research shows that ultrasound has been safely used in medical imaging for many years. Studies have found no evidence of harm from its use, even in sensitive areas like pregnancy care. Ultrasound, a well-known tool that uses low-power sound waves, carries no known risks.

Photoacoustic imaging, a newer method, combines light and sound to create detailed images. It helps doctors see tissue structures and gather important information. Current studies on photoacoustic imaging are promising, but detailed safety data remain limited. Early findings suggest it could improve cancer diagnosis without any safety issues.

In summary, ultrasound is known to be safe, while photoacoustic imaging is still under study, with no major safety concerns reported so far.12345

Why are researchers excited about this trial?

Researchers are excited about the use of photoacoustic imaging combined with ultrasound for assessing ovarian health because it offers a new way to visualize and understand the condition of the ovaries. Unlike standard transvaginal ultrasounds, which primarily use sound waves to create images, photoacoustic imaging adds a layer of detail by using laser-induced ultrasound to provide insights into tissue composition and blood oxygenation. This dual approach could potentially allow for earlier detection and better characterization of ovarian issues, which is something current methods struggle to achieve. By enhancing the detail and information obtained from imaging, this technique could lead to more precise monitoring and treatment strategies for individuals at high risk.

What evidence suggests that the photoacoustic imaging/ultrasound technique is effective for ovarian health?

This trial will evaluate the combination of photoacoustic imaging and ultrasound for ovarian health. Studies have shown that combining photoacoustic imaging with ultrasound holds great promise for early detection of ovarian cancer. This technique can accurately differentiate between cancerous and non-cancerous ovarian growths, with a high success rate. Photoacoustic imaging can also detect higher levels of hemoglobin, a sign of invasive ovarian cancers, aiding in their identification. Ultrasound alone is already effective in identifying ovarian issues, with some studies showing up to 97.2% accuracy. When combined, these imaging methods offer a powerful way to diagnose ovarian health problems, potentially reducing unnecessary surgeries while still effectively detecting cancer. Participants in this trial will undergo both imaging methods to assess their effectiveness in a clinical setting.14567

Who Is on the Research Team?

CL

Cary L Siegel, M.D.

Principal Investigator

Washington University School of Medicine

Are You a Good Fit for This Trial?

This trial is for adults who may carry certain genetic mutations linked to ovarian cancer (like BRCA1/2) and are referred for surgery that includes removal of at least one ovary. Participants should be willing to be monitored for 1-2 years before deciding on preventive ovary removal.

Inclusion Criteria

My ovarian cancer has a harmful mutation in a specific gene.
I am willing to be monitored for 1-2 years before deciding on preventive ovary removal.
I am willing and able to give my consent to participate in the study.
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Imaging

Baseline transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging for all participants enrolled

1 day
1 visit (in-person)

Surgical Procedure and Imaging

Once the surgeon has surgically removed the ovary(ies), they will be imaged with the photoacoustic imaging/ultrasound

At the time of surgery (estimated to be 2 weeks)

Exploratory Imaging Follow-up

For high-risk participants, transvaginal ultrasound and photoacoustic imaging will be performed at 6, 12, 18, 24 months, and at the time of surgery

24 months
Multiple visits (in-person)

Menstrual Cycle Imaging

For a subset of high-risk participants, imaging will be performed every 2 weeks at follicular and luteal phases for 3 months

3 months
Multiple visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4.5 years

What Are the Treatments Tested in This Trial?

Interventions

  • Photoacoustic imaging
  • Ultrasound
Trial Overview The study tests if photoacoustic imaging, combined with ultrasound, can reduce unnecessary surgeries while still effectively detecting ovarian cancer, especially in early stages among high-risk patients.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Transvaginal photoacoustic imaging/ultrasoundExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials
2,027
Recruited
2,353,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Published Research Related to This Trial

Multispectral optoacoustic tomography (MSOT) is a promising imaging technique that can produce high-contrast, high-resolution images at depths of up to 5 cm, which could enhance medical diagnostics.
For MSOT to be effectively used in clinical settings, it needs improvements in probe design and data acquisition systems, as well as more user-friendly real-time visualization tools.
Development of Multispectral Optoacoustic Tomography as a Clinically Translatable Modality for Cancer Imaging.MacCuaig, WM., Jones, MA., Abeyakoon, O., et al.[2023]
The OPUS system combines optoacoustic imaging with ultrasound technology, allowing for enhanced breast cancer detection by providing additional information about tissue absorption without major modifications to existing ultrasound equipment.
This system enables the generation of 2D and 3D images of optical absorption in tissues, which can be quantitatively analyzed to assess absorber concentrations, improving diagnostic capabilities in medical imaging.
Combined optoacoustic/ultrasound system for tomographic absorption measurements: possibilities and limitations.Haisch, C., Eilert-Zell, K., Vogel, MM., et al.[2016]
In a study of 92 breast masses assessed using optoacoustic ultrasound, higher scores for external features (like hemoglobin levels and vessel abnormalities) were significantly associated with malignant masses, indicating a strong predictive value for cancer (p < 0.0001).
The findings suggest that optoacoustic ultrasound can effectively differentiate between benign and malignant breast masses, particularly by focusing on external features, which may help address challenges in distinguishing between the two based solely on morphology.
Optoacoustic Breast Imaging: Imaging-Pathology Correlation of Optoacoustic Features in Benign and Malignant Breast Masses.Butler, R., Lavin, PT., Tucker, FL., et al.[2019]

Citations

A Coregistered Ultrasound and Photoacoustic Imaging ...Combined with coregistered ultrasound (US), PAT has demonstrated great potential for detecting ovarian cancers and for accurately diagnosing ovarian lesions for ...
Coregistered Photoacoustic and Ultrasound Imaging for Ovarian ...The new imaging device will also be used to screen a small group of women who have increased risk of ovarian cancer to determine its effectiveness on early ...
Photoacoustic tomography reconstruction using lag-based ...DMAS-LAG-CF can improve cancer diagnosis with an AUC of 0.91 for distinguishing malignant vs. benign ovarian lesions when mean and skewness are used as ...
Optical Resolution Photoacoustic Microscopy of Ovary and ...This manuscript reports the first study of OR-PAM for imaging and quantification of microvascular components of human ovary and fallopian tube.
Evaluation of Ovarian Cancer: Initial Application ...The coregistered photoacoustic and US technique showed higher relative total hemoglobin concentration in invasive epithelial ovarian cancers ...
Transvaginal Ultrasound and Photoacoustic Imaging of OvaryThis study is being conducted to validate if photoacoustic imaging potentially reduces benign surgeries without compromising cancer detection sensitivity. The ...
Mini review of photoacoustic clinical imaging: a noninvasive ...Photoacoustic (PA) imaging is an emerging medical imaging technique that enables detailed visualization of tissue structures and functional information.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security